BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E. External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. Br J Clin Pharmacol 2013;75:1068-80. [PMID: 23148919 DOI: 10.1111/j.1365-2125.2012.04406.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 11.2] [Reference Citation Analysis]
Number Citing Articles
1 Tauzin M, Tréluyer J, Nabbout R, Billette de Villemeur T, Desguerre I, Aboura R, Gana I, Zheng Y, Benaboud S, Bouazza N, Chenevier-gobeaux C, Freihuber C, Hirt D. Simulations of Valproate Doses Based on an External Evaluation of Pediatric Population Pharmacokinetic Models. The Journal of Clinical Pharmacology 2019;59:406-17. [DOI: 10.1002/jcph.1333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Wang YL, Guilhaumou R, Blin O, Velly L, Marsot A. External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients. Eur J Clin Pharmacol 2020;76:1281-9. [PMID: 32495084 DOI: 10.1007/s00228-020-02922-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Li X, Qi H, Jin F, Yao BF, Wu YE, Qi YJ, Kou C, Wu XR, Luo XJ, Shen YH, Zheng X, Wang YH, Xu F, Jiao WW, Li JQ, Xiao J, Dong YN, Du B, Shi HY, Xu BP, Shen AD, Zhao W. Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis. Eur J Pharm Sci 2021;163:105868. [PMID: 33951483 DOI: 10.1016/j.ejps.2021.105868] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tang BH, Guan Z, Allegaert K, Wu YE, Manolis E, Leroux S, Yao BF, Shi HY, Li X, Huang X, Wang WQ, Shen AD, Wang XL, Wang TY, Kou C, Xu HY, Zhou Y, Zheng Y, Hao GX, Xu BP, Thomson AH, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Burggraaf J, Jacqz-Aigrain E, van den Anker J, Zhao W. Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction. Clin Pharmacokinet 2021. [PMID: 34041714 DOI: 10.1007/s40262-021-01033-x] [Reference Citation Analysis]
5 Brou NA, Jacqz-Aigrain E, Zhao W. Cystatin C as a potential biomarker for dosing of renally excreted drugs. Br J Clin Pharmacol 2015;80:20-7. [PMID: 25655191 DOI: 10.1111/bcp.12602] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
6 Zhao YC, Zou Y, Xiao YW, Wang F, Zhang BK, Xiang DX, Yu F, Luo H, Sandaradura I, Yan M. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients. Infect Dis Ther 2021. [PMID: 34748194 DOI: 10.1007/s40121-021-00551-2] [Reference Citation Analysis]
7 Zhao W, Biran V, Jacqz-aigrain E. Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates. Clin Pharmacokinet 2013;52:1127-34. [DOI: 10.1007/s40262-013-0101-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
8 Talaie H, Mousavizadeh A, Emami H, Gachkar L, Barari B, Alijanzadeh MH. High sensitivity versus low level of vancomycin needs to be concern for another alternative anti- Staphylococcus aureus as the first- line antibiotic. Acta Biomed 2019;90:498-503. [PMID: 31910175 DOI: 10.23750/abm.v90i4.7646] [Reference Citation Analysis]
9 Dao K, Guidi M, André P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister M, Buclin T, Csajka C. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research 2020;154:104278. [DOI: 10.1016/j.phrs.2019.104278] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
10 Tang BH, Wu YE, Kou C, Qi YJ, Qi H, Xu HY, Leroux S, Huang X, Zhou Y, Zheng Y, Jacqz-Aigrain E, Shen AD, Zhao W. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. Antimicrob Agents Chemother 2019;63:e02336-18. [PMID: 30509939 DOI: 10.1128/AAC.02336-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
11 Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, Castellan C, Kassai B, van den Anker JN, Kearns GL, Turner MA, Jacqz-Aigrain E; TINN Consortium. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. Antimicrob Agents Chemother 2014;58:6572-80. [PMID: 25155587 DOI: 10.1128/AAC.03568-14] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
12 Maharaj AR, Wu H, Hornik CP, Arrieta A, James L, Bhatt-Mehta V, Bradley J, Muller WJ, Al-Uzri A, Downes KJ, Cohen-Wolkowiez M. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. J Pharmacokinet Pharmacodyn 2020;47:199-218. [PMID: 32323049 DOI: 10.1007/s10928-020-09684-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol 2014;10:1069-78. [PMID: 24961300 DOI: 10.1517/17425255.2014.931937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
14 Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, Baruchel A, Jacqz-Aigrain E. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease. Antimicrob Agents Chemother 2014;58:3191-9. [PMID: 24663023 DOI: 10.1128/AAC.02564-13] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
15 Santacana E, Rodríguez-alonso L, Padullés A, Guardiola J, Rodríguez-moranta F, Serra K, Bas J, Morandeira, Biology F, Colom H, Padullés N. External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring 2018;40:120-9. [DOI: 10.1097/ftd.0000000000000476] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
16 Tasa T, Metsvaht T, Kalamees R, Vilo J, Lutsar I. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates. Therapeutic Drug Monitoring 2017;39:604-13. [DOI: 10.1097/ftd.0000000000000456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
17 Jacqz-Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Nakamura H, van den Anker JN, Sharland M, Zhao W. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. J Antimicrob Chemother 2019;74:2128-38. [PMID: 31049551 DOI: 10.1093/jac/dkz158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
18 Sampson MR, Frymoyer A, Rattray B, Cotten CM, Smith PB, Capparelli E, Bonifacio SL, Cohen-Wolkowiez M. Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia. Ther Drug Monit 2014;36:584-9. [PMID: 25225917 DOI: 10.1097/FTD.0000000000000056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Janssen EJ, Välitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother 2016;60:1013-21. [PMID: 26643337 DOI: 10.1128/AAC.01968-15] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 7.2] [Reference Citation Analysis]
20 Roberts JK, Stockmann C, Constance JE, Stiers J, Spigarelli MG, Ward RM, Sherwin CMT. Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants. Clin Pharmacokinet 2014;53:581-610. [DOI: 10.1007/s40262-014-0147-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
21 Allegaert K, van den Anker JN. Clinical pharmacology in neonates: small size, huge variability. Neonatology 2014;105:344-9. [PMID: 24931327 DOI: 10.1159/000360648] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
22 Lv C, Lu J, Jing L, Liu TT, Chen M, Zhang R, Li C, Zhou S, Wei Y, Chen Y. Systematic external evaluation of reported population pharmacokinetic models of vancomycin in Chinese children and adolescents. J Clin Pharm Ther 2021;46:820-31. [PMID: 33751618 DOI: 10.1111/jcpt.13363] [Reference Citation Analysis]
23 Liu YX, Wen H, Niu WJ, Li JJ, Li ZL, Jiao Z. External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers. Front Pharmacol 2021;12:623907. [PMID: 33897418 DOI: 10.3389/fphar.2021.623907] [Reference Citation Analysis]
24 Le J, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. J Clin Pharmacol 2018;58 Suppl 10:S108-22. [PMID: 30248202 DOI: 10.1002/jcph.1128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
25 Okada A, Kariya M, Irie K, Okada Y, Hiramoto N, Hashimoto H, Kajioka R, Maruyama C, Kasai H, Hamori M, Nishimura A, Shibata N, Fukushima K, Sugioka N. Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation. The Journal of Clinical Pharmacology 2018;58:1140-9. [DOI: 10.1002/jcph.1106] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
26 Girardi A, Raschi E, Galletti S, Allegaert K, Poluzzi E, De Ponti F. Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development. Expert Opin Drug Metab Toxicol 2017;13:555-65. [PMID: 28141945 DOI: 10.1080/17425255.2017.1290081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Smits A, Kulo A, van den Anker J, Allegaert K. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Expert Opin Drug Metab Toxicol 2017;13:157-66. [PMID: 27623706 DOI: 10.1080/17425255.2017.1234606] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
28 De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res 2014;31:2643-54. [PMID: 24789450 DOI: 10.1007/s11095-014-1361-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
29 Zhao CY, Jiao Z, Mao JJ, Qiu XY. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 2016;81:891-907. [PMID: 26574188 DOI: 10.1111/bcp.12830] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
30 Leroux S, van den Anker JN, Smits A, Pfister M, Allegaert K. Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates. Br J Clin Pharmacol 2019;85:865-7. [PMID: 30834552 DOI: 10.1111/bcp.13899] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
31 Allegaert K, Flint R, Smits A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin Drug Metab Toxicol 2019;15:735-49. [PMID: 31402708 DOI: 10.1080/17425255.2019.1655540] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
32 Leroux S, Roué JM, Gouyon JB, Biran V, Zheng H, Zhao W, Jacqz-Aigrain E. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. Antimicrob Agents Chemother 2016;60:6626-34. [PMID: 27572399 DOI: 10.1128/AAC.01045-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
33 Samardzic J, Smits A, Spriet I, Soldatovic I, Atkinson A, Bajcetic M, Van Den Anker JN, Allegaert K. Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates. Biomed Res Int 2016;2016:1974972. [PMID: 27635396 DOI: 10.1155/2016/1974972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 van Beek SW, Ter Heine R, Keizer RJ, Magis-Escurra C, Aarnoutse RE, Svensson EM. Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin. Clin Pharmacokinet 2019;58:815-26. [PMID: 30671890 DOI: 10.1007/s40262-018-00732-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
35 Tauzin M, Cohen R, Durrmeyer X, Dassieu G, Barre J, Caeymaex L. Continuous-Infusion Vancomycin in Neonates: Assessment of a Dosing Regimen and Therapeutic Proposal. Front Pediatr 2019;7:188. [PMID: 31139607 DOI: 10.3389/fped.2019.00188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
36 Abdulla A, Edwina AE, Flint RB, Allegaert K, Wildschut ED, Koch BCP, de Hoog M. Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review. Front Pediatr 2021;9:624639. [PMID: 33708753 DOI: 10.3389/fped.2021.624639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
37 Chen CY, Li MY, Ma LY, Zhai XY, Luo DH, Zhou Y, Liu ZM, Cui YM. Precision and accuracy of commercial assays for vancomycin therapeutic drug monitoring: evaluation based on external quality assessment scheme. J Antimicrob Chemother 2020;75:2110-9. [PMID: 32464644 DOI: 10.1093/jac/dkaa150] [Reference Citation Analysis]
38 Padari H, Oselin K, Tasa T, Metsvaht T, Lõivukene K, Lutsar I. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatr 2016;16:206. [PMID: 27931193 DOI: 10.1186/s12887-016-0753-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
39 Ter Heine R, Keizer RJ, van Steeg K, Smolders EJ, van Luin M, Derijks HJ, de Jager CPC, Frenzel T, Brüggemann R. Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. Br J Clin Pharmacol 2020;86:2497-506. [PMID: 32415710 DOI: 10.1111/bcp.14360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. How to use vancomycin optimally in neonates: remaining questions. Expert Rev Clin Pharmacol 2015;8:635-48. [PMID: 26289222 DOI: 10.1586/17512433.2015.1060124] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
41 Allegaert K, Smits A, van den Anker JN. Drug evaluation studies in neonates: how to overcome the current limitations. Expert Rev Clin Pharmacol 2018;11:387-96. [PMID: 29421929 DOI: 10.1080/17512433.2018.1439378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wang DD, Chen X, Fu M, Zheng QS, Xu H, Li ZP. Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica 2020;50:371-9. [PMID: 31192749 DOI: 10.1080/00498254.2019.1631505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
43 Germovsek E, Osborne L, Gunaratnam F, Lounis SA, Busquets FB, Standing JF, Sinha AK. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data. J Antimicrob Chemother 2019;74:1003-11. [PMID: 30668696 DOI: 10.1093/jac/dky525] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
44 Chung E, Sen J, Patel P, Seto W. Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review. Clin Pharmacokinet 2021;60:985-1001. [PMID: 34002357 DOI: 10.1007/s40262-021-01027-9] [Reference Citation Analysis]
45 Ryu S, Jung WJ, Jiao Z, Chae JW, Yun HY. External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates. Br J Clin Pharmacol 2021;87:3878-89. [PMID: 33638184 DOI: 10.1111/bcp.14803] [Reference Citation Analysis]
46 Vandendriessche A, Allegaert K, Cossey V, Naulaers G, Saegeman V, Smits A. Prospective validation of neonatal vancomycin dosing regimens is urgently needed. Curr Ther Res Clin Exp 2014;76:51-7. [PMID: 25061483 DOI: 10.1016/j.curtheres.2014.06.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
47 Moffett BS, Humlicek TJ, Akcan-Arikan A, Anders M, Tume S. Population Pharmacokinetics of Vancomycin in the Pediatric Ventricular Assist Device Population. Pediatr Crit Care Med 2020;21:e566-71. [PMID: 32224831 DOI: 10.1097/PCC.0000000000002349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister M. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. J Clin Pharmacol 2016;56:909-35. [PMID: 26766774 DOI: 10.1002/jcph.705] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
49 Tauzin M, Tréluyer JM, Nabbout R, Billette de Villemeur T, Desguerre I, Aboura R, Gana I, Zheng Y, Benaboud S, Bouazza N, Chenevier-Gobeaux C, Freihuber C, Hirt D. Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models. J Clin Pharmacol 2021;61:677-87. [PMID: 33244764 DOI: 10.1002/jcph.1791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 van den Anker JN. The impact of therapeutic drug monitoring in neonatal clinical pharmacology. Clin Biochem 2014;47:704-5. [PMID: 24854683 DOI: 10.1016/j.clinbiochem.2014.05.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
51 Mao JJ, Jiao Z, Yun HY, Zhao CY, Chen HC, Qiu XY, Zhong MK. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. Br J Clin Pharmacol 2018;84:153-71. [PMID: 28891596 DOI: 10.1111/bcp.13431] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
52 Zhao W, Leroux S, Jacqz-Aigrain E. Dosage individualization in children: integration of pharmacometrics in clinical practice. World J Pediatr 2014;10:197-203. [PMID: 25124969 DOI: 10.1007/s12519-014-0493-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
53 Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother 2014;58:6454-61. [PMID: 25136027 DOI: 10.1128/AAC.03620-14] [Cited by in Crossref: 66] [Cited by in F6Publishing: 29] [Article Influence: 9.4] [Reference Citation Analysis]
54 Zheng Y, Liu SP, Xu BP, Shi ZR, Wang K, Yang JB, Huang X, Tang BH, Chen XK, Shi HY, Zhou Y, Wu YE, Qi H, Jacqz-Aigrain E, Shen AD, Zhao W. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. Antimicrob Agents Chemother 2018;62:e00686-18. [PMID: 29941652 DOI: 10.1128/AAC.00686-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
55 Samardzic J, Turner MA, Bax R, Allegaert K. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol 2015;11:1041-52. [PMID: 25958820 DOI: 10.1517/17425255.2015.1046433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
56 van den Anker J, Allegaert K. Rational Use of Antibiotics in Neonates: Still in Search of Tailored Tools. Healthcare (Basel) 2019;7:E28. [PMID: 30781454 DOI: 10.3390/healthcare7010028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
57 Allegaert K. Better medicines for neonates: Improving medicine development, testing, and prescribing. Early Hum Dev 2017;114:22-5. [PMID: 28899617 DOI: 10.1016/j.earlhumdev.2017.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
58 Thirion DJG, Pasche V, Matouk E, Marsot A. Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Pediatr Pulmonol 2020;55:1154-60. [PMID: 32119197 DOI: 10.1002/ppul.24689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
59 Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert Opin Drug Metab Toxicol 2016;12:367-75. [PMID: 26817821 DOI: 10.1517/17425255.2016.1147559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
60 Zhao Y, Yao BF, Kou C, Xu HY, Tang BH, Wu YE, Hao GX, Zhang XP, Zhao W. Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants. Front Pharmacol 2020;11:14. [PMID: 32116695 DOI: 10.3389/fphar.2020.00014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Ther Drug Monit 2015;37:756-65. [PMID: 26562817 DOI: 10.1097/FTD.0000000000000216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
62 Cheng Y, Wang CY, Li ZR, Pan Y, Liu MB, Jiao Z. Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations. Clin Pharmacokinet 2021;60:53-68. [PMID: 32960439 DOI: 10.1007/s40262-020-00937-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Zhang HX, Sheng CC, Liu LS, Luo B, Fu Q, Zhao Q, Li J, Liu YF, Deng RH, Jiao Z, Wang CX. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus. Br J Clin Pharmacol 2019;85:746-61. [PMID: 30597603 DOI: 10.1111/bcp.13850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
64 Oyaert M, Peersman N, Kieffer D, Deiteren K, Smits A, Allegaert K, Spriet I, Van Eldere J, Verhaegen J, Vermeersch P, Pauwels S. Novel LC–MS/MS method for plasma vancomycin: Comparison with immunoassays and clinical impact. Clinica Chimica Acta 2015;441:63-70. [DOI: 10.1016/j.cca.2014.12.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
65 Gu J, Guo Y, Jiao Z, Ding J, Li G. How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective. Eur J Drug Metab Pharmacokinet 2020;45:163-72. [DOI: 10.1007/s13318-019-00598-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
66 Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates. Arch Dis Child 2016;101:377-81. [DOI: 10.1136/archdischild-2013-305309] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
67 Ward RM, Allegaert K, de Groot R, van den Anker JN. Commentary: Continuous infusion of vancomycin in neonates: to use or not to use remains the question. Pediatr Infect Dis J 2014;33:606-7. [PMID: 24378934 DOI: 10.1097/INF.0000000000000244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Bhongsatiern J, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB, Sherwin CM. Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance? J Clin Pharmacol 2016;56:528-40. [PMID: 26412385 DOI: 10.1002/jcph.650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]